IGM Biosciences: Funding, Investors & Team (Oct 2026)
IGM Biosciences is a biotechnology company that is at the clinical stage of developing engineered IgM antibodies for the treatment of various diseases. These antibodies have unique properties that make them more effective at binding to cell surfaces compared to IgG antibodies. The company's technology platform is well-suited for creating T cell engagers, receptor cross-linking agonists, targeted cytokines, and target neutralizers. The main product candidate of IGM Biosciences is Imvotamab, which is a bispecific IgM antibody that targets CD20 and CD3 proteins to engage T cells. It is currently being tested in Phase 2 clinical trials for the treatment of relapsed and/or refractory large B cell lymphoma and follicular lymphoma. The company's second product candidate, IGM-8444, is an IgM antibody that targets Death Receptor 5 (DR5) for the treatment of patients with relapsed and/or refractory solid and hematologic malignancies. It is in Phase 1 clinical trials. Additionally, IGM-7354 and IGM-2644 are also in the company's product pipeline. IGM-7354 is an IgM antibody that targets PD-L1 expressing cells to deliver interleukin-15 (IL-15) cytokines for the treatment of patients with solid and hematologic malignancies. IGM-2644 is a bispecific IgM antibody that targets CD38 and CD3 proteins for the treatment of patients with multiple myeloma.
IGM Biosciences has raised $107M across 1 funding round on record, the most recent an undisclosed round of $107M announced in Jun 2023.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
IGM Biosciences Company Profile and Key Stats
Latest funding round on record: Jun 2023.
IGM Biosciences Funding Rounds
IGM Biosciences Founders and Leadership Team
Contact details for the IGM Biosciences team: 1 of 1 has an email address on file.
Start 14-day free trial →IGM Biosciences Funding Compared to Other Biotechnology Startups
IGM Biosciences' latest round of $107M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like IGM Biosciences in Biotechnology and Mountain View
Companies Similar to IGM Biosciences
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
IGM Biosciences Funding FAQs
What does IGM Biosciences do?
IGM Biosciences is a biotechnology company that is at the clinical stage of developing engineered IgM antibodies for the treatment of various diseases. These antibodies have unique properties that make them more effective at binding to cell surfaces compared to IgG antibodies. The company's technology platform is well-suited for creating T cell engagers, receptor cross-linking agonists, targeted cytokines, and target neutralizers. The main product candidate of IGM Biosciences is Imvotamab, which is a bispecific IgM antibody that targets CD20 and CD3 proteins to engage T cells. It is currently being tested in Phase 2 clinical trials for the treatment of relapsed and/or refractory large B cell lymphoma and follicular lymphoma. The company's second product candidate, IGM-8444, is an IgM antibody that targets Death Receptor 5 (DR5) for the treatment of patients with relapsed and/or refractory solid and hematologic malignancies. It is in Phase 1 clinical trials. Additionally, IGM-7354 and IGM-2644 are also in the company's product pipeline. IGM-7354 is an IgM antibody that targets PD-L1 expressing cells to deliver interleukin-15 (IL-15) cytokines for the treatment of patients with solid and hematologic malignancies. IGM-2644 is a bispecific IgM antibody that targets CD38 and CD3 proteins for the treatment of patients with multiple myeloma.
How much funding has IGM Biosciences raised?
IGM Biosciences has raised $107M across 1 round on record. The most recent is an undisclosed round of $107M announced in Jun 2023.
When did IGM Biosciences last raise funding?
IGM Biosciences' most recent funding round on record is an undisclosed round of $107M, announced in Jun 2023.
Who founded IGM Biosciences?
FundedIQ lists Fred Schwarzer (Founder) at IGM Biosciences.
Where is IGM Biosciences headquartered?
IGM Biosciences is based in Mountain View, California, United States.
How many employees does IGM Biosciences have?
IGM Biosciences is in the 251-500 employee band.
How does IGM Biosciences' funding compare to other Biotechnology startups?
IGM Biosciences' latest round of $107M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's IGM Biosciences Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for IGM Biosciences is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.